Total Payments
$11,828
2024 Payments
$2,477
Companies
33
Transactions
358
Medicare Patients
2,049
Medicare Billing
$235,931
Payment Breakdown by Category
Food & Beverage$11,828 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,828 | 358 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,600 | 116 | $0 (2024) |
| Gilead Sciences, Inc. | $2,352 | 50 | $0 (2024) |
| Janssen Biotech, Inc. | $711.28 | 20 | $0 (2024) |
| Celgene Corporation | $571.93 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $546.85 | 5 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $523.37 | 5 | $0 (2024) |
| Allergan, Inc. | $423.89 | 30 | $0 (2020) |
| GENZYME CORPORATION | $398.00 | 5 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $311.32 | 21 | $0 (2021) |
| Phathom Pharmaceuticals, Inc. | $223.67 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,477 | 39 | ABBVIE INC. ($747.59) |
| 2023 | $2,350 | 46 | ABBVIE INC. ($866.54) |
| 2022 | $1,704 | 25 | ABBVIE INC. ($490.49) |
| 2021 | $688.19 | 10 | Gilead Sciences, Inc. ($154.29) |
| 2020 | $25.50 | 2 | Allergan, Inc. ($12.76) |
| 2019 | $1,237 | 48 | AbbVie, Inc. ($608.10) |
| 2018 | $1,483 | 89 | Gilead Sciences, Inc. ($411.88) |
| 2017 | $1,862 | 99 | AbbVie, Inc. ($386.60) |
All Payment Transactions
358 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $143.76 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.17 | General |
| 12/05/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $3.72 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFLAM | ||||||
| 11/14/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $9.15 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $3.65 | General |
| Category: LIVER DISEASE | ||||||
| 10/23/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $124.22 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.45 | General |
| 10/09/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $108.61 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/25/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | Cash or cash equivalent | $124.98 | General |
| Category: Immunology | ||||||
| 09/17/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $130.22 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $9.06 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/30/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $149.61 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/23/2024 | ABBVIE INC. | CREON (Drug), LINZESS, VIBERZI | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $124.47 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.45 | General |
| Category: Neuroscience | ||||||
| 07/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.61 | General |
| 07/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/10/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.41 | General |
| Category: Neuroscience | ||||||
| 06/25/2024 | Janssen Scientific Affairs, LLC | STELARA (Biological) | Food and Beverage | In-kind items and services | $94.71 | General |
| Category: Immunology | ||||||
| 06/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: IMMUNOLOGY | ||||||
| 05/29/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.42 | General |
| Category: Neuroscience | ||||||
| 05/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.97 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 494 | 500 | $980,790 | $58,245 |
| 2022 | 11 | 471 | 479 | $538,310 | $56,140 |
| 2021 | 12 | 582 | 587 | $256,172 | $63,840 |
| 2020 | 11 | 502 | 513 | $220,825 | $57,705 |
Total Patients
2,049
Total Services
2,079
Medicare Billing
$235,931
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 133 | 133 | $379,629 | $26,231 | 6.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 60 | 60 | $87,067 | $10,116 | 11.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 128 | 128 | $235,350 | $6,217 | 2.6% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 61 | 61 | $156,338 | $5,033 | 3.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 22 | 22 | $27,519 | $3,646 | 13.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 28 | 28 | $66,000 | $2,772 | 4.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 42 | $4,104 | $2,596 | 63.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $24,643 | $1,543 | 6.3% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Facility | 2023 | 14 | 14 | $140.08 | $91.08 | 65.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 122 | 122 | $186,410 | $22,970 | 12.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 55 | 55 | $48,981 | $9,511 | 19.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 105 | 105 | $120,812 | $6,068 | 5.0% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 53 | 56 | $104,011 | $4,663 | 4.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 27 | 27 | $29,401 | $3,628 | 12.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 32 | 32 | $32,846 | $3,047 | 9.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 15 | 15 | $10,447 | $2,624 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 26 | $2,577 | $1,651 | 64.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $1,621 | $1,058 | 65.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 12 | $805.68 | $589.99 | 73.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 17 | 17 | $398.31 | $330.42 | 83.0% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 142 | 142 | $70,971 | $27,202 | 38.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 60 | 60 | $21,807 | $10,447 | 47.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 114 | 115 | $48,422 | $6,013 | 12.4% |
| 43249 | Balloon dilation of esophagus, stomach and upper small bowel using a flexible endoscope | Facility | 2021 | 57 | 59 | $72,254 | $4,477 | 6.2% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 28 | 28 | $9,808 | $3,386 | 34.5% |
About Dr. Ramez Khoury, MD
Dr. Ramez Khoury, MD is a Gastroenterology healthcare provider based in Janesville, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780743682.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ramez Khoury, MD has received a total of $11,828 in payments from pharmaceutical and medical device companies, with $2,477 received in 2024. These payments were reported across 358 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($11,828).
As a Medicare-enrolled provider, Khoury has provided services to 2,049 Medicare beneficiaries, totaling 2,079 services with total Medicare billing of $235,931. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Janesville, WI
- Active Since 12/06/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1780743682
Products in Payments
- Epclusa (Drug) $1,495
- ZEPOSIA (Drug) $1,094
- STELARA (Biological) $943.16
- RINVOQ (Biological) $865.27
- SKYRIZI (Biological) $653.43
- LINZESS (Drug) $578.54
- DUPIXENT (Biological) $489.35
- Mavyret (Drug) $468.44
- Humira (Biological) $461.40
- VIBERZI (Drug) $319.19
- CREON (Drug) $312.90
- Creon (Drug) $273.67
- TREMFYA (Drug) $252.45
- VOQUEZNA (Drug) $223.67
- IBSRELA (Drug) $220.16
- Entyvio (Biological) $197.04
- Cimzia (Drug) $186.14
- REZDIFFRA (Drug) $143.76
- OMVOH (Drug) $143.73
- Livdelzi (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.